ISDA

Deposition Date 2013-09-17

Release Date 2013-10-02

Last Version Date 2024-05-08

Entry Detail

PDB ID:

4C66

Keywords:

CELL CYCLE

Title:

Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains

Biological Source:

Source Organism:

HOMO SAPIENS (Taxon ID: 9606)

Host Organism:

ESCHERICHIA COLI

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.87 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:BROMODOMAIN-CONTAINING PROTEIN 4
Gene (Uniprot):BRD4
Chain IDs:A
Chain Length:126
Number of Molecules:1
Biological Source:HOMO SAPIENS

UniProt ID:O60885 Pfam ID:PF00439

Primary Citation

Discovery of Epigenetic Regulator I-Bet762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the Bet Bromodomains.

Mirguet, O, Gosmini, R, Toum, J, Clement, C, Barnathan, M, Brusq, J, Mordaunt, J.E, Grimes, R, Crowe, M, Pineau, O, Ajakane, M, Daugan, A, Jeffrey, P, Cutler, L, Haynes, A, Smithers, N, Chung, C, Bamborough, P, Uings, I.J, Lewis, T, Witherington, J, Parr, N, Prinjha, R, Nicodeme, E.Show

J.Med.Chem. 56 7501 ? (2013)

PMID: 24015967 DOI: 10.1021/JM401088K

Abstact

The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.

Legend

Protein

Chemical

Disease

Primary Citation of related structures